Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
about
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analysesCardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-AnalysesThe Different Therapeutic Choices with ARBs. Which One to Give? When? Why?Management of diabetic renal diseaseAngiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-AnalysisAssessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data.Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy.Management of Hypertension Using Olmesartan Alone or in CombinationSystematic review automation technologies.Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design.Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.Urinary fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray.Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trialDrug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-AnalysisEmerging drug combinations to optimize renovascular protection and blood pressure goals.Effect of Behavior Modification on Outcome in Early- to Moderate-Stage Chronic Kidney Disease: A Cluster-Randomized Trial.Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.Short Term Safety and Tolerability of a Fixed Dose Combination of Olmesartan, Amlodipine and HydrochlorothiazideRenin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure).The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney diseaseAngiotensin II blockade and renal protection.Linear mixed-effects model of QTc prolongation for olmesartan medoxomil.A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval.Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice.The challenges of comparing results between placebo controlled randomized trials and non-experimental new user, active comparator cohort studies: the example of olmesartan.Angiotensin receptor blockers in clinical practice--implications of the ONTARGET study.An evaluation of the latest evidence relating to renin-angiotensin system inhibitors.To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.The Nrf2 pathway in the progression of renal disease.Renin-angiotensin system blocking drugs.The effect of RAAS blockade on the progression of diabetic nephropathy.Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.The Role of Beta-Blockers in the Treatment of Hypertension.
P2860
Q26766025-ED179C1A-C0AA-431D-B49F-E16C9097B323Q26767278-6D982035-8B19-4F3E-B73B-3A934610A365Q26768696-25729211-FB92-46B4-850C-7243DB55D4F2Q26798436-080E4197-1117-47DB-A3E0-B4EE60348E61Q26851803-AFBC1278-BAC4-4DDC-9EBD-343F27F95EB0Q26863404-F818E8AC-DBC5-4111-9033-88C7D8A23BAAQ31123979-69C7AFCD-0F56-4192-BE2E-257053B011D0Q33603422-69E26B8B-F538-4DE8-9569-4888F7B6D294Q33734043-C5104587-82AF-4131-B137-FB5EF58A7160Q33910187-EBC17AEB-052D-4311-95D2-F7DC26BF1D6CQ34196851-FD69C74C-8109-4195-BD70-A13F1EC8F3CBQ34273029-C71566B2-D9FC-49B1-8EC7-0855EC1B8D43Q34380070-3B122B45-DE1C-4FCC-BC9F-4B674EE81CE4Q35001942-8149E64A-1650-46B3-8431-11D9B3063DD3Q35021685-26535449-BC2D-44BE-B1D1-78786F01DC4EQ35738903-4749B580-5EAD-43AC-85A5-5CAAEB3F97B4Q35811038-6C03195E-D828-41D5-ABCD-C54731F604B4Q35903126-996BD2B1-1319-409C-8AA1-DB06B9451774Q35905899-3B0AF046-0841-41FA-BF2F-6085090BDC00Q35964981-47C5A507-AD03-4B6E-82F0-01C2F2C2D5D8Q36058755-7C95A5F4-4B66-4969-B0C6-03B17465574BQ36077409-962AE01E-E530-439A-8A5E-0D397B9039D0Q36329456-90D2BEF1-3480-4653-9FC7-60119416E75FQ36603772-D0A639A3-733E-4289-B804-3DE5F7E9438DQ36675029-F4ADE572-E0EB-4D07-8115-CD6F3BE79799Q36836004-677447F9-2480-48C9-A9E5-146892D908DCQ37309014-37EEE68F-096E-48DB-91FD-F4DB5B63B67DQ37337313-0775118B-A99E-40D2-A78D-74CEAB38F484Q37369476-B871806A-9E29-4BE5-991C-9CE6DB276AE5Q37681363-DE11E9AE-062B-42D1-813F-583D8CD12CE0Q37731789-E4EFFE71-3496-4693-9BD9-7FD8757E490EQ37994859-566671F9-6436-410B-AC3F-641ABD7AEF2FQ38096442-AB9984B0-9F69-4F69-92DD-CB7C0B263451Q38098108-E86F6DDC-FA1A-4F3A-A667-50C59D16CC0AQ38114031-3D74B338-9984-40BA-A3F8-0816F8427055Q38137851-1C71CFFE-3CBC-447B-BD94-EF4C2509FA3BQ38168046-CD1C8387-2A24-4C0F-A2B4-33FF4AA66B97Q38553908-EA86EF63-E68B-4412-B784-1838B1B7DB89Q38732291-F846250B-0B25-4970-951C-A7C1787D76FEQ38783696-9E8DCB63-9869-4347-BB94-1B64FBAC4AA1
P2860
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effects of olmesartan on renal ...... sed, placebo-controlled study.
@ast
Effects of olmesartan on renal ...... sed, placebo-controlled study.
@en
type
label
Effects of olmesartan on renal ...... sed, placebo-controlled study.
@ast
Effects of olmesartan on renal ...... sed, placebo-controlled study.
@en
prefLabel
Effects of olmesartan on renal ...... sed, placebo-controlled study.
@ast
Effects of olmesartan on renal ...... sed, placebo-controlled study.
@en
P2093
P2860
P921
P1433
P1476
Effects of olmesartan on renal ...... ised, placebo-controlled study
@en
P2093
F Kobayashi
ORIENT study investigators
T Yamasaki
P2860
P2888
P304
P356
10.1007/S00125-011-2325-Z
P577
2011-10-13T00:00:00Z